Roles
- Associate Professor of Clinical Ophthalmology
-
Biography
Dr. Nicolas A. Yannuzzi is vitreoretinal surgeon at Bascom Palmer Eye Institute where he completed his residency in ophthalmology and fellowship in vitreoretinal surgery and served as a chief resident and the co-director of ocular trauma. Dr. Yannuzzi received his B.A. from Harvard College where he graduated cum laude with high honors in biochemical sciences. Subsequently, he spent a dedicated research year at Memorial Sloan-Kettering Cancer Center examining novel treatments for glioblastoma, the most fatal form of brain cancer. Dr. Yannuzzi received his medical degree at Weill Cornell Medical College where he won the Edward Norton prize in ophthalmology and was elected to the Alpha Omega Alpha honors society. He then returned to Sloan-Kettering where he completed his transitional internship and conducted research in pediatric eye cancer. He is a lead or co-author in over 75 peer reviewed manuscripts in ophthalmology and retinal disease and has delivered over 30 presentations at national meetings. He is also the recipient of the Heed and Michels' Fellowship Awards. -
Education & Training
Education
-
Research Interests
Healthcare Economics
Retinal Imaging
Optical Coherence Tomography Angiography
Rhegmatogenous Retinal Detachment
Anti-VEGF Therapy
Endophthalmitis -
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 3 clinical trials.
-
This phase 2b/3 partially masked, randomized, multicenter study will enroll approximately 300 participants with neovascular age-related macular degeneration (nAMD) who meet the inclusion/exclusion criteria. The study is designed to evaluate the efficacy and safety of RGX-314 following a single injection and to evaluate the efficacy and safety of RGX-314 relative to an active comparator, Lucentis, for 54 weeks.
- Principal Investigator: Nicolas Yannuzzi
- Study Phase: Phase II/III
- Enrollment Status: Closed
-
A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
- Principal Investigator: Nicolas Yannuzzi
- Study Phase: Phase 2
- Enrollment Status: Closed
-
The human body is made up of cells and it is believed that these aging cells accumulate as people get older and contribute to the inflammation and pain associated with diabetic macular edema (DME). An investigational drug is being developed by the Sponsor of the study for the treatment of DME.
- Principal Investigator: Nicolas Yannuzzi
- Study Phase: Phase II
- Enrollment Status: Closed
